Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus TNT in locally advanced rectal cancer
NCT04906044Phase 1Active, not recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Jun 2021
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sintilimab in rectal cancer, sponsored by The First Hospital of Jilin University. Primary endpoint: Incidence of serious adverse events at 1 year. Started Jun 2021; status: active, not recruiting.
02
Drugs
sintilimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04906044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04906044.